Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction (Q44121977)

30 November 2017

title

Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction (English)

1 reference

30 November 2017

0 references

0 references

myocardial infarction

1 reference

Koh-ichi Wada

1 reference

30 November 2017

Atsuo Tahara

1 reference

30 November 2017

Yukinori Arai

1 reference

30 November 2017

Motonori Aoki

1 reference

30 November 2017

Yuichi Tomura

1 reference

30 November 2017

Junko Tsukada

1 reference

30 November 2017

Takeyuki Yatsu

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

European Journal of Pharmacology

30 November 2017

published in

1 reference

30 November 2017

volume

450

1 reference

30 November 2017

1 reference

30 November 2017

page(s)

169-177

1 reference

Stimulation of 42/44kDa mitogen-activated protein kinases by arginine vasopressin in rat cardiomyocytes

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Attenuation of Genetic Hypertension After Short-term Vasopressin V1A Receptor Antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Validation of an echocardiographic assessment of cardiac function following moderate size myocardial infarction in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

The effect of vasopressin V1- and V2-receptor antagonists on hemodynamics in early and late phase after myocardial infarction in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Increased plasma arginine vasopressin levels in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Arginine vasopressin and the renal response to water loading in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Neurohumoral responses to chronic myocardial infarction in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Early captopril prevents myocardial infarction-induced hypertrophy but not angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Vascular and renal effects of vasopressin and its antagonists in conscious rats with chronic myocardial infarction; evidence for receptor shift

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Hyponatraemia as a marker for high renin heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Hormonal, global, and regional haemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Myocardial infarct size and ventricular function in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Antidiuretic hormone in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Mechanisms of impaired cardiac function by vasopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Plasma ADH level in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902101-5

10.1016/S0014-2999(02)02101-5

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference